{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-008617","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.201440+00:00","generated_at":"2026-05-24T09:26:14.338245+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaxart reports FY2024 net loss $66.9M, revenue $28.7M; initiates Phase 1 norovirus trial","bullets":["Net loss $66.9M ($0.33/sh) vs $82.5M in 2023; revenue $28.7M (up from $7.4M).","Cash $51.7M provides runway into Q4 2025; workforce reduced ~10% after COVID trial stop-work order.","Phase 1 trial of second-gen norovirus vaccine started; topline data expected mid-2025.","COVID-19 Phase 2b sentinel cohort enrolled; U.S. government stop-work order issued, only per-protocol follow-up allowed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-008617","json":"https://secwatch.observer/filing/0001437749-25-008617.json","markdown":"https://secwatch.observer/filing/0001437749-25-008617.md","text":"https://secwatch.observer/filing/0001437749-25-008617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925008617/0001437749-25-008617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925008617/vxrt20250320_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T09:26:14.338245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}